This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pandolfino, T. L. Articles by Guitart, J. Search for Related Content PubMed PubMed Citation Articles by Pandolfino, T. L. Articles by Guitart, J. Social Bookmarking                            What's this?

Primary Cutaneous B-Cell Lymphoma: Review and Current Concepts

From the Department of Dermatology, Department of Medicine, Section of Hematology and Oncology, Northwestern University Medical School; and Robert H. Lurie Cancer Center, Chicago, IL.

Address reprint requests to Tomi L. Pandolfino, MD, Department of Dermatology, Northwestern University, 675 N St Clair, Suite 19-150, Chicago, IL 60611; email j-guitart{at}nwu.edu

ABSTRACT

PURPOSE: Primary cutaneous B-cell lymphoma (PCBCL) has only recently been recognized as a distinct clinical entity. With the advent of improved immunophenotyping and immunogenotyping, increasing numbers of PCBCL cases are being diagnosed. However, there is much confusion regarding the classification, treatment, and prognosis of these patients. The purpose of this article is to review and analyze the available data to provide the clinician with a concise summary of the diagnosis, prognosis, and treatment of PCBCL.

DESIGN: We conducted a thorough review of the medical literature on PCBCL, with a focus on classification, prognosis, and treatment trials.

RESULTS AND CONCLUSION: PCBCL is defined as a B-cell lymphoma originating in the skin. There is no evidence of extracutaneous disease at presentation and for 6 months after diagnosis, as assessed by adequate staging procedures. Currently, the European Organization for Research and Treatment of Cancer classification is the most concise disease classification scheme, dividing the subtypes of PCBCL by clinical behavior and histopathologic findings. Based on this classification, the most common subtype of PCBCL is follicular center cell lymphoma. PCBCL is generally an indolent form of lymphoma with a good prognosis. Although local cutaneous recurrences are observed in 25% to 68% of patients, dissemination to internal organs is rare. Five-year survival rates typically range from 89% to 96%. A specific subtype, large B-cell lymphoma of the leg, is noted to have a poorer prognosis, with a 5-year survival rate of 58%. Overly aggressive treatment of PCBCL has not been shown to improve survival or prevent relapse. The treatment of choice usually varies depending on the type of PCBCL, the body surface area, and the location of the involvement, as well as the age and general health condition of the patient. The majority of studies indicate that PCBCL is highly responsive to radiation therapy. Polychemotherapy should be reserved for involvement of noncontiguous anatomic sites or those with extracutaneous spread.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Valencak, F. Weihsengruber, K. Rappersberger, F. Trautinger, A. Chott, B. Streubel, L. Muellauer, M. Der-Petrossian, C. Jonak, M. Binder, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients Ann. Onc., February 1, 2009; 20(2): 326 - 330. [Abstract] [Full Text] [PDF]

				M. A. Habra, E. J. Weaver, and P. V. Prewitt III Primary Cutaneous Large B-Cell Lymphoma of the Leg and Acute Hypercalcemia J. Clin. Oncol., December 20, 2007; 25(36): 5825 - 5826. [Full Text] [PDF]

				N. J. Senff, J. J. Hoefnagel, P. M. Jansen, M. H. Vermeer, J. van Baarlen, W. A. Blokx, M. R. Canninga-van Dijk, M.-L. Geerts, K. M. Hebeda, P. M. Kluin, et al. Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO-EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers J. Clin. Oncol., April 20, 2007; 25(12): 1581 - 1587. [Abstract] [Full Text] [PDF]

				E. Zambrano, O. Mejia-Mejia, C. Bifulco, J. Shin, and M. Reyes-Mugica Extranodal Marginal Zone B-Cell Lymphoma/Maltoma of the Lip in a Child: Case Report and Review of Cutaneous Lymphoid Proliferations in Childhood International Journal of Surgical Pathology, April 1, 2006; 14(2): 163 - 169. [Abstract] [PDF]

				B. D. Smith, G. L. Smith, D. L. Cooper, and L. D. Wilson The Cutaneous B-Cell Lymphoma Prognostic Index: A Novel Prognostic Index Derived From a Population-Based Registry J. Clin. Oncol., May 20, 2005; 23(15): 3390 - 3395. [Abstract] [Full Text] [PDF]

				F. M. Raaphorst Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R93 - R100. [Abstract] [Full Text] [PDF]

				K. K. Sra, M. Babb-Tarbox, S. Aboutalebi, P. Rady, G. L. Shipley, D. D. Dao, and S. K. Tyring Molecular Diagnosis of Cutaneous Diseases Arch Dermatol, February 1, 2005; 141(2): 225 - 241. [Abstract] [Full Text] [PDF]

				B. D. Smith, E. J. Glusac, J. M. McNiff, G. L. Smith, P. W. Heald, D. L. Cooper, and L. D. Wilson Primary Cutaneous B-Cell Lymphoma Treated With Radiotherapy: A Comparison of the European Organization for Research and Treatment of Cancer and the WHO Classification Systems J. Clin. Oncol., February 15, 2004; 22(4): 634 - 639. [Abstract] [Full Text] [PDF]

				F. M. Raaphorst, M. Vermeer, E. Fieret, T. Blokzijl, D. Dukers, R. G.A.B. Sewalt, A. P. Otte, R. Willemze, and C. J.L.M. Meijer Site-Specific Expression of Polycomb-Group Genes Encoding the HPC-HPH/PRC1 Complex in Clinically Defined Primary Nodal and Cutaneous Large B-Cell Lymphomas Am. J. Pathol., February 1, 2004; 164(2): 533 - 542. [Abstract] [Full Text] [PDF]

				J. T. Trent, P. Romanelli, and F. A. Kerdel Topical Targretin and Intralesional Interferon Alfa for Cutaneous Lymphoma of the Scalp Arch Dermatol, November 1, 2002; 138(11): 1421 - 1423. [Full Text] [PDF]

				C. Visco, L. J. Medeiros, D. Jones, T. Smith, M. A. Rodriguez, P. McLaughlin, J. Romaguera, F. Cabanillas, and A. H. Sarris Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement Ann. Onc., August 1, 2002; 13(8): 1290 - 1299. [Abstract] [Full Text] [PDF]

				I. Mirza, N. Macpherson, S. Paproski, R. D. Gascoyne, B. Yang, W. G. Finn, and E. D. Hsi Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features J. Clin. Oncol., February 1, 2002; 20(3): 647 - 655. [Abstract] [Full Text] [PDF]

				J. M. Connors, E. D. Hsi, and F. M. Foss Lymphoma of the Skin Hematology, January 1, 2002; 2002(1): 263 - 282. [Abstract] [Full Text]

				N. V. Kamath, A. C. Gilliam, M. Nihal, T. P. Spiro, and G. S. Wood Primary Cutaneous Large B-Cell Lymphoma of the Leg Relapsing as Cutaneous Intravascular Large B-Cell Lymphoma Arch Dermatol, December 1, 2001; 137(12): 1657 - 1658. [Full Text] [PDF]

				A. H. Sarris, I. Braunschweig, L. J. Medeiros, M. Duvic, C. S. Ha, M. A. Rodriguez, F. B. Hagemeister, P. McLaughlin, J. Romaguera, J. Cox, et al. Primary Cutaneous Non-Hodgkin's Lymphoma of Ann Arbor Stage I: Preferential Cutaneous Relapses but High Cure Rate With Doxorubicin-Based Therapy J. Clin. Oncol., January 15, 2001; 19(2): 398 - 405. [Abstract] [Full Text] [PDF]